Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: bleomycin sulfate
Drug: EPOCH regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2009-09-24

Last Posted Date: 2017-11-30

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT00983944

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Phase 1

Terminated

Conditions: Relapsed T-Cell Lymphoblastic Lymphoma
Relapsed T-Cell Acute Lymphoblastic Leukemia

Interventions: Drug: Nelarabine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Filgrastim

First Posted Date: 2009-09-22

Last Posted Date: 2020-10-01

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 23

Registration Number: NCT00981799

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Texas at Southwestern, Dallas, Texas, United States
🇺🇸
University of Miami Cancer Center, Miami, Florida, United States

and more 34 locations

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: figitumumab
Drug: Cisplatin (Or Carboplatin)
Drug: Etoposide

First Posted Date: 2009-09-15

Last Posted Date: 2013-02-25

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT00977561

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2009-09-09

Last Posted Date: 2011-11-03

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 60

Registration Number: NCT00973882

Locations: 🇫🇷
Centre Val d'Aurelle, Montpellier, France
🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Centre François Baclesse, Caen, France

and more 8 locations

Infusion of Expanded Cord Blood T Cells

Phase 1

Withdrawn

Conditions: Stem Cell Transplantation
Leukemia
Lymphoma
Pediatric Disorders

Interventions: Drug: Melphalan
Radiation: Total Body Irradiation (TBI)
Drug: Thiotepa
Drug: Fludarabine
Drug: Etoposide
Drug: Rituximab
Drug: Anti-thymocyte globulin (ATG)
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus
Procedure: Cord Blood Infusion
Drug: G-CSF
Procedure: Ex vivo expanded T cell Infusion

First Posted Date: 2009-09-04

Last Posted Date: 2012-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00972101

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Phase 1

Completed

Conditions: B-cell Lymphoma
Lymphoma

Interventions: Procedure: Leukapheresis
Procedure: Stem Cell Transplant
Procedure: CD19-specific T Cell Infusion
Drug: Carmustine
Drug: IL-2
Drug: Etoposide
Drug: Melphalan
Drug: Cytarabine

First Posted Date: 2009-08-31

Last Posted Date: 2023-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00968760

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Phase 2

Completed

Conditions: Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions: Drug: Bortezomib
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide

First Posted Date: 2009-08-27

Last Posted Date: 2020-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00967369

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1

Terminated

Conditions: Bone Cancer
Neoplasms
Solid Tumors
Neuroblastoma
Kidney Tumor

Interventions: Drug: Temozolomide
Drug: Vincristine
Drug: Ifosfamide
Drug: Irinotecan
Biological: Robatumumab
Drug: Doxorubicin
Drug: Etoposide
Drug: Cyclophosphamide

First Posted Date: 2009-08-17

Last Posted Date: 2018-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 4

Registration Number: NCT00960063

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Phase 2

Terminated

Conditions: Relapsed Acute Myelogenous Leukemia

Interventions: Drug: Clofarabine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Cytarabine

First Posted Date: 2009-07-15

Last Posted Date: 2020-02-19

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 6

Registration Number: NCT00939653

Locations: 🇺🇸
University of Miami Cancer Center, Miami, Florida, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Memorial, Chicago, Illinois, United States

and more 1 locations

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Phase 2

Completed

Conditions: Testicular Cancer

Interventions: Drug: Gemcitabine
Drug: Docetaxel
Drug: Mesna
Drug: Melphalan
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-10

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00936936

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy